PL2646464T3 - Przeciwnowotworowe białko fuzyjne - Google Patents

Przeciwnowotworowe białko fuzyjne

Info

Publication number: PL2646464T3
Authority: PL; Poland
Prior art keywords: fusion protein; anticancer fusion; anticancer; protein; fusion
Prior art date: 2010-12-03

Application number

PL11790636T

Other languages

English (en)

Inventor

Jerzy Szczepan Pieczykolan

Krzysztof Kazimierz Lemke

Sebastian Pawlak

Bartłomiej Źerek

Original Assignee

Adamed Pharma Spolka Akcyjna

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-12-03

Filing date

2011-12-05

Publication date

2015-10-30

2010-12-03 Priority claimed from PL393146A external-priority patent/PL393146A1/pl

2011-12-05 Application filed by Adamed Pharma Spolka Akcyjna filed Critical Adamed Pharma Spolka Akcyjna

2015-10-30 Publication of PL2646464T3 publication Critical patent/PL2646464T3/pl

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/217—IFN-gamma
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/57—IFN-gamma
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Zoology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biochemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Biophysics (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Toxicology (AREA)
Cell Biology (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Wood Science & Technology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Microbiology (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

PL11790636T 2010-12-03 2011-12-05 Przeciwnowotworowe białko fuzyjne PL2646464T3 (pl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
PL393146A PL393146A1 (pl)	2010-12-03	2010-12-03	Przeciwnowotworowe białko fuzyjne
PL39459711		2011-04-18
EP11790636.2A EP2646464B1 (en)	2010-12-03	2011-12-05	Anticancer fusion protein
PCT/EP2011/071719 WO2012072815A1 (en)	2010-12-03	2011-12-05	Anticancer fusion protein

Publications (1)

Publication Number	Publication Date
PL2646464T3 true PL2646464T3 (pl)	2015-10-30

Family

ID=45065918

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL11790636T PL2646464T3 (pl)	2010-12-03	2011-12-05	Przeciwnowotworowe białko fuzyjne

Country Status (27)

Country	Link
US (1)	US9161991B2 (pl)
EP (1)	EP2646464B1 (pl)
JP (1)	JP5759557B2 (pl)
KR (1)	KR101952460B1 (pl)
CN (1)	CN103237808B (pl)
AU (1)	AU2011334868B2 (pl)
BR (1)	BR112013013548B8 (pl)
CA (1)	CA2814595C (pl)
CY (1)	CY1116646T1 (pl)
DK (1)	DK2646464T3 (pl)
EA (1)	EA024452B1 (pl)
ES (1)	ES2545895T3 (pl)
HR (1)	HRP20150664T1 (pl)
HU (1)	HUE027068T2 (pl)
IL (1)	IL226207A (pl)
ME (1)	ME02224B (pl)
MX (1)	MX337436B (pl)
NZ (1)	NZ609216A (pl)
PH (1)	PH12013500714A1 (pl)
PL (1)	PL2646464T3 (pl)
PT (1)	PT2646464E (pl)
RS (1)	RS54057B1 (pl)
SG (2)	SG189370A1 (pl)
SI (1)	SI2646464T1 (pl)
SM (1)	SMT201500203B (pl)
WO (1)	WO2012072815A1 (pl)
ZA (1)	ZA201303449B (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL219845B1 (pl) *	2011-01-05	2015-07-31	Adamed Spółka Z Ograniczoną Odpowiedzialnością	Przeciwnowotworowe białko fuzyjne
EP2670426B1 (en) *	2011-01-31	2017-05-10	The General Hospital Corporation	Multimodal trail molecules and uses in cellular therapies
WO2014018113A1 (en)	2012-07-24	2014-01-30	The General Hospital Corporation	Oncolytic virus therapy for resistant tumors
US9605074B2 (en)	2012-08-30	2017-03-28	The General Hospital Corporation	Multifunctional nanobodies for treating cancer
WO2014057436A2 (en)	2012-10-10	2014-04-17	Adamed Sp. Z O.O.	Anticancer conjugate
WO2014141094A1 (en)	2013-03-14	2014-09-18	Adamed Sp. Z O.O.	Anticancer conjugate
WO2016127346A1 (zh) *	2015-02-11	2016-08-18	四川大学华西医院	一种肿瘤坏死因子相关凋亡诱导配体变异体及其制备方法和用途
CN106632682A (zh) *	2015-08-04	2017-05-10	清华大学	融合蛋白ifn-elp及其应用
EP3955957A1 (en)	2019-04-15	2022-02-23	Qwixel Therapeutics LLC	Fusion protein composition(s) comprising targeted masked type i interferons (ifna and ifnb) and an antibody against tumor antigen, for use in the treatment of cancer
BR112022020440A2 (pt)	2020-04-10	2022-12-27	Cytomx Therapeutics Inc	Construtos de citocinas ativáveis e composições e métodos relacionados
EP4308594A2 (en)	2021-03-16	2024-01-24	CytomX Therapeutics, Inc.	Masked activatable cytokine constructs and related compositions and methods
KR102839482B1 (ko)	2022-06-09	2025-07-25	제주대학교 산학협력단	Trail을 포함하는 탈모 증상의 예방, 개선 또는 치료용 조성물 및 이의 용도
KR20240068191A (ko)	2022-11-10	2024-05-17	제주대학교 산학협력단	리모닌을 유효성분으로 포함하는 탈모 증상의 예방, 개선 또는 치료용 조성물 및 이의 용도
KR102925278B1 (ko)	2022-11-17	2026-02-09	제주대학교 산학협력단	감귤 무봉 추출물을 유효성분으로 포함하는 탈모증상의 예방 개선 또는 치료용 조성물
CN116143945A (zh) *	2022-12-09	2023-05-23	浙江大学杭州国际科创中心	一种趋化因子与免疫检查点抑制剂融合表达蛋白及其生产方法和应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6936694B1 (en)	1982-05-06	2005-08-30	Intermune, Inc.	Manufacture and expression of large structural genes
ES2253753T3 (es)	1995-06-29	2006-06-01	Immunex Corporation	Citocina que induce apoptosis.
DK1351709T3 (da) *	2000-06-09	2005-01-31	Us Gov Health & Human Serv	Pegylering af linkere forbedrer antitumorvirkning og reducerer immunkonjugaters tokcitet
EP1581615B1 (en) *	2000-09-05	2010-04-28	Biosight Ltd	Peptide conjugated anti-cancer prodrugs
DE10247755B4 (de)	2002-10-14	2006-01-19	Pfizenmaier, Klaus, Prof. Dr.	Selektive, lokale Aktivierung von Mitgliedern der TNF-Rezeptorfamilie durch systemisch inaktive nicht-Antikörper-TNF-Liganden-Fusionsproteine
ATE501256T1 (de)	2003-11-03	2011-03-15	Beijing Sunbio Biotech Co Ltd	Rekombinantes protein mit krebsunterdrückender wirkung, sein codierendes gen und seine verwendung
RU2409817C2 (ru)	2005-08-16	2011-01-20	Дженентек, Инк.	Анализы и способы применения биомаркеров
WO2009002947A2 (en)	2007-06-22	2008-12-31	Affymax, Inc.	Compounds and peptides that bind the trail receptor
CA2692802C (en) *	2007-07-10	2017-05-30	Oliver Hill	Tnf superfamily collectin fusion proteins
CA3128656A1 (en)	2007-08-22	2009-02-26	The Regents Of The University Of California	Activatable binding polypeptides and methods of identification and use thereof
GB0723059D0 (en)	2007-11-23	2008-01-02	Nat Univ Ireland	Improved cytokine design
GB0724532D0 (en)	2007-12-17	2008-01-30	Nat Univ Ireland	Trail variants for treating cancer
WO2009086132A2 (en)	2007-12-20	2009-07-09	University Of Southern California	Design of spacers to increase the expression of recombinant fusion proteins
WO2009140469A2 (en)	2008-05-14	2009-11-19	Genentech, Inc.	Methods of using apo2l/trail to treat cancer
LT2010012A (lt)	2010-02-10	2011-08-25	Uab Profarma, ,	Granulocitus stimuliuojančio baltymo linijiniai oligomerai su prailginta in vivo gyvavimo trukme

2011
- 2011-12-05 ES ES11790636.2T patent/ES2545895T3/es active Active
- 2011-12-05 WO PCT/EP2011/071719 patent/WO2012072815A1/en not_active Ceased
- 2011-12-05 CA CA2814595A patent/CA2814595C/en active Active
- 2011-12-05 HU HUE11790636A patent/HUE027068T2/en unknown
- 2011-12-05 PT PT117906362T patent/PT2646464E/pt unknown
- 2011-12-05 DK DK11790636.2T patent/DK2646464T3/en active
- 2011-12-05 PL PL11790636T patent/PL2646464T3/pl unknown
- 2011-12-05 SG SG2013027479A patent/SG189370A1/en unknown
- 2011-12-05 AU AU2011334868A patent/AU2011334868B2/en active Active
- 2011-12-05 PH PH1/2013/500714A patent/PH12013500714A1/en unknown
- 2011-12-05 NZ NZ609216A patent/NZ609216A/en unknown
- 2011-12-05 CN CN201180057053.1A patent/CN103237808B/zh active Active
- 2011-12-05 SI SI201130524T patent/SI2646464T1/sl unknown
- 2011-12-05 US US13/989,969 patent/US9161991B2/en active Active
- 2011-12-05 HR HRP20150664TT patent/HRP20150664T1/hr unknown
- 2011-12-05 RS RS20150407A patent/RS54057B1/sr unknown
- 2011-12-05 KR KR1020137017194A patent/KR101952460B1/ko active Active
- 2011-12-05 ME MEP-2015-89A patent/ME02224B/me unknown
- 2011-12-05 EP EP11790636.2A patent/EP2646464B1/en active Active
- 2011-12-05 SG SG10201509676UA patent/SG10201509676UA/en unknown
- 2011-12-05 BR BR112013013548A patent/BR112013013548B8/pt active IP Right Grant
- 2011-12-05 EA EA201390820A patent/EA024452B1/ru unknown
- 2011-12-05 JP JP2013541381A patent/JP5759557B2/ja active Active
- 2011-12-05 MX MX2013006213A patent/MX337436B/es active IP Right Grant
2013
- 2013-05-07 IL IL226207A patent/IL226207A/en active IP Right Grant
- 2013-05-13 ZA ZA2013/03449A patent/ZA201303449B/en unknown
2015
- 2015-08-25 SM SM201500203T patent/SMT201500203B/xx unknown
- 2015-08-25 CY CY20151100743T patent/CY1116646T1/el unknown

Also Published As

Publication number	Publication date
EP2646464A1 (en)	2013-10-09
RS54057B1 (sr)	2015-10-30
JP2014502158A (ja)	2014-01-30
ZA201303449B (en)	2014-01-29
EP2646464B1 (en)	2015-06-03
WO2012072815A1 (en)	2012-06-07
BR112013013548B8 (pt)	2022-11-08
CN103237808A (zh)	2013-08-07
CA2814595A1 (en)	2012-06-07
NZ609216A (en)	2014-05-30
JP5759557B2 (ja)	2015-08-05
DK2646464T3 (en)	2015-08-24
BR112013013548B1 (pt)	2022-03-29
SG189370A1 (en)	2013-05-31
KR20130122764A (ko)	2013-11-08
IL226207A (en)	2016-07-31
BR112013013548A2 (pt)	2016-10-11
EA201390820A1 (ru)	2013-12-30
US9161991B2 (en)	2015-10-20
HRP20150664T1 (hr)	2015-07-31
IL226207A0 (en)	2013-07-31
PT2646464E (pt)	2015-10-05
CA2814595C (en)	2020-06-16
HK1186192A1 (en)	2014-03-07
EA024452B1 (ru)	2016-09-30
ES2545895T3 (es)	2015-09-16
SMT201500203B (it)	2015-10-30
KR101952460B1 (ko)	2019-02-27
HUE027068T2 (en)	2016-08-29
CN103237808B (zh)	2016-02-24
MX337436B (es)	2016-03-03
MX2013006213A (es)	2013-07-29
AU2011334868A1 (en)	2013-05-02
ME02224B (me)	2016-02-20
AU2011334868B2 (en)	2015-01-22
US20130251676A1 (en)	2013-09-26
CY1116646T1 (el)	2017-03-15
SI2646464T1 (sl)	2015-07-31
SG10201509676UA (en)	2015-12-30
PH12013500714A1 (en)	2013-06-10

Publication	Publication Date	Title
ZA201300677B (en)	2013-09-25	Anticancer fusion protein
ZA201404667B (en)	2015-09-30	Anticancer fusion protein
ZA201303449B (en)	2014-01-29	Anticancer fusion protein
GB201113558D0 (en)	2011-09-21	Kraftfahrzeugkarosserie mit strukturverstarkter vorderrahmenanbindung
SG10202100341XA (en)	2021-02-25	Npp1 fusion proteins
SMT201700300T1 (it)	2017-07-18	"proteina di fusione anticancro
ZA201405460B (en)	2015-04-29	Anticancer fusion protein
GB201116180D0 (en)	2011-11-02	Kraftfahrzeug mit warnsystem
IL226481A0 (en)	2013-07-31	Enzymes@Maochim
EP2698386B8 (en)	2018-02-07	Fusion protein
EP2657337A4 (en)	2014-09-17	FUSION PROTEIN
ZA201308597B (en)	2014-12-23	Anticancer fusion protein
PL2809342T3 (pl)	2017-06-30	Peptyd dwufunkcyjny
GB201016494D0 (en)	2010-11-17	Polypeptide
ZA201207425B (en)	2014-03-26	Fusion protein
EP2521787A4 (en)	2013-11-13	IMPROVED PROTEIN EXPRESSION
GB201016346D0 (en)	2010-11-10	Connection means
PL393146A1 (pl)	2012-06-04	Przeciwnowotworowe białko fuzyjne
GB201007955D0 (en)	2010-06-30	Somatosatin fusion proteins
HK1189602A (en)	2014-06-13	Anticancer fusion protein
GB201010202D0 (en)	2010-07-21	Fusion polypeptides
GB201114701D0 (en)	2011-10-12	Fusion proteins
GB201107189D0 (en)	2011-06-15	Fusion proteins
ZA201301851B (en)	2013-11-27	Pharmaceutical combinations
GB201104152D0 (en)	2011-04-27	Fusion Polypeptide